Navigation Links
Novel experimental agent is highly active in CLL patients, interim study shows
Date:12/11/2011

COLUMBUS, Ohio An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, called PCI-32765, is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) is available to discuss the findings that were presented today (12/13) at the 53rd Annual Meeting of the American Society of Hematology in San Diego.

Study co-leader Dr. Susan O'Brien of The University of Texas M.D. Anderson Cancer Center reported the analysis, which involves 61 patients who have relapsed and whose cancer no longer responds to standard CLL therapy. Of these patients, 27 received a drug dose of 420 milligrams (mg) and 34 received a drug dose of 840 mg.

This study found that 70 percent of patients in the 420-mg group had either a complete or partial remission to treatment after 10 months of follow-up.

"These interim findings are truly exciting because they provide additional evidence that PCI-32765 is a highly active oral therapeutic that produces a high rate of durable remissions the remissions last months on end with acceptable toxicity in relapsed and refractory CLL," Byrd says. "These responses last for many months in part because patients are willing to remain on the drug since the side effects are very tolerable," he notes.

Complete remission means there is no detectable CLL anywhere in the body; partial remission means that the individual's disease volume has decr
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Evolve Medical Clinics ... 2014, offering its members virtual visits and dramatic operational changes ... , Some estimates state that as many as 70% of ... “Imagine not having to leave your office or home for ... blood pressure or cholesterol,” CEO and Founder Michael R. Freedman, ...
(Date:7/28/2014)... 28, 2014 Ticket Down is ... Champions Cup Match between Manchester City and Liverpool FC ... Bronx has hosted countless big events since it opened several ... of the original Yankee Stadium, however, it has been a ... City metro area. , The Yankees Stadium is the ...
(Date:7/28/2014)... Scottsdale, Ariz (PRWEB) July 28, 2014 ... closed on a new camp property in Cornville, ... provides seriously ill children with the opportunity to ... the campers and families. The organization offers a ... ages 6-15 with chronic and life threatening illnesses ...
(Date:7/28/2014)... Quincy Bioscience, makers of the nation’s ... announce the release of the fourth edition of The ... Mark Underwood. , The Brain Health Guide is a ... for readers to improve memory and promote optimal aging. ... Brain Health Guide provides ways to help minimize common ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
Breaking Medicine News(10 mins):Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 3Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 4Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3
... The Men,s Health Policy,Center, a new resource center ... that they are hosting an online petition urging,Congress ... Services (CMS) practice,that unfairly restricts prostate cancer patients, ... people who are impacted by prostate cancer to,raise ...
... The Richard B. and,Lynne V. Cheney Cardiovascular ... have joined the Institute,s Board of Directors. As ... Institute., "Mary Matalin,s experience in public affairs ... Institute as we build our organization and educate,communities ...
... Have Choices and Flexibility ... Typically Available on Larger Plans, NEW YORK, March ... employees can now choose from a wider selection of dental ... The Guardian Life Insurance Company of America (Guardian), a ...
... 27, 2008 The Cardiovascular Research Foundation (CRF) will ... mortality rates for drug-eluting stents (DES) versus bare metal ... tomorrow evening in Chicago. , The analysiswhich includes ... team of researchers led by Ajay J. Kirtane, MD, ...
... relaxation response, a stress-management approach, to other lifestyle ... of hypertension most common in the elderly. ... Massachusetts General Hospital (MGH) Hypertension Program and the ... who received relaxation response training in addition to ...
... There is new promise on the horizon for ... according to researchers at the University of Toronto. ... twitches and muscle contractions during rapid eye-movement (REM) sleep, ... at the University of Toronto, discovered that an inhibitory ...
Cached Medicine News:Health News:Men's Health Policy Center Hosts Petition to Protest Government Barrier to Prostate Cancer Medications 2Health News:Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 3Health News:Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use 2Health News:Relaxation training may improve control of hard-to-treat systolic hypertension 2Health News:Relaxation training may improve control of hard-to-treat systolic hypertension 3
(Date:7/28/2014)... -- ResMed (NYSE: RMD ), an innovator and ... breathing and other chronic respiratory conditions, has won a ... Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting ... and 220 masks.  The judgment was entered by the ... is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)... England , July 28, 2014 /PRNewswire/ ... dass Albion Ventures 2,5 Millionen £ investiert ... in der Konsumgüter-, Gesundheits-, Pharma- und Logistikbranche ... Ventures.      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ... 18 Monaten hat OmPrompt sein beschleunigtes Wachstum ...
(Date:7/28/2014)... 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... release its second quarter and year-to-date 2014 financial results ... the U.S. financial markets. The earnings press release will ... Company,s website, www.anipharmaceuticals.com . Arthur ... Charlotte C. Arnold , Vice President and Chief ...
Breaking Medicine Technology:ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope ... and patient comfort. The latest in ... an increased light guide, and a wide ... very impressive 3.3mm distal tip diameter. ...
... Articulating Tip Laryngoscopes are the ... Industry. The articulating tip aids ... an improved view of epiglottis. ... Optic styles. We guarantee your ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical conventional laryngoscopes....
Medicine Products: